Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 7:5:1345929.
doi: 10.3389/falgy.2024.1345929. eCollection 2024.

Oral immunotherapy with enteric-coated capsules for allergic rhinitis caused by house dust mites

Han-Zhong Zhang #  1 , Wei Xie #  1 , Wen-Cheng Zhou #  2 , Jian Chen  1 , Ying Wang  1 , Yuan-Yuan Zhu  1 , Ting-Huan Wen  3 , Lei Cheng  2   4
Affiliations

Oral immunotherapy with enteric-coated capsules for allergic rhinitis caused by house dust mites

Han-Zhong Zhang et al. Front Allergy. .

Abstract

Background: Oral immunotherapy (OIT) is a promising allergen-specific approach in the management of food allergy; however, studies on OIT for allergic rhinitis (AR) have rarely been reported. The purpose of this study is to evaluate the efficacy and safety of OIT using enteric-coated capsules for AR induced by house dust mites.

Methods: A total of 49 patients with AR were enrolled, including 25 who received subcutaneous immunotherapy (SCIT) and 24 who received OIT. The clinical efficacy and safety in both groups were evaluated.

Results: After 1 year of treatment, both SCIT and OIT demonstrated significant therapeutic effects. OIT was found to be more effective than SCIT in reducing the total AR symptom score and improving the results of nasal provocation tests. Local and systemic adverse reactions were observed in the SCIT group, while none were reported in the OIT group.

Conclusion: OIT is an effective and safe treatment for mite-induced AR.

Keywords: allergic rhinitis; enteric-coated capsules; mites; oral immunotherapy; subcutaneous immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

    1. Cheng L, Chen J, Fu Q, He S, Li H, Liu Z, et al. Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. (2018) 10:300–53. 10.4168/aair.2018.10.4.300 - DOI - PMC - PubMed
    1. Pavon-Romero GF, Parra-Vargas MI, Ramirez-Jimenez F, Melgoza-Ruiz E, Serrano-Perez NH, Teran LM. Allergen immunotherapy: current and future trends. Cells. (2022) 11:212. 10.3390/cells11020212 - DOI - PMC - PubMed
    1. Klimek L, Sperl A, Becker S, Mosges R, Tomazic PV. Current therapeutical strategies for allergic rhinitis. Expert Opin Pharmacother. (2019) 20:83–9. 10.1080/14656566.2018.1543401 - DOI - PubMed
    1. Fukuda K, Ishida W, Wakasa Y, Takagi H, Takaiwa F, Fukushima A. Oral immunotherapy for allergic conjunctivitis using transgenic rice expressing hypoallergenic antigens. Cornea. (2018) 37(Suppl 1):S67–73. 10.1097/ICO.0000000000001758 - DOI - PubMed
    1. Chaaban MR, Mansi A, Tripple JW, Wise SK. SCIT versus SLIT: which one do you recommend, doc? Am J Med Sci. (2019) 357:442–7. 10.1016/j.amjms.2019.02.004 - DOI - PubMed